These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32081246)

  • 41. Impact of IVUS-Derived Vessel Size on Midterm Outcomes After Stent Implantation in Femoropopliteal Lesions.
    Miki K; Fujii K; Tanaka T; Yanaka K; Yoshihara N; Nishimura M; Sumiyoshi A; Horimatsu T; Imanaka T; Fukunaga M; Akahori H; Masuyama T; Ishihara M
    J Endovasc Ther; 2020 Feb; 27(1):77-85. PubMed ID: 31948376
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluation of mortality following paclitaxel drug-coated stent angioplasty of femoropopliteal lesions in real world.
    Böhme T; Noory E; Beschorner U; Jacques B; Bürgelin K; Macharzina R; Nührenberg T; Cheung F; Neumann FJ; Zeller T
    Catheter Cardiovasc Interv; 2020 Nov; 96(6):1306-1314. PubMed ID: 32930497
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease: Evidence From the SFA-Long Study.
    Micari A; Vadalà G; Castriota F; Liso A; Grattoni C; Russo P; Marchese A; Pantaleo P; Roscitano G; Cesana BM; Cremonesi A
    JACC Cardiovasc Interv; 2016 May; 9(9):950-6. PubMed ID: 27151609
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K; Ullery BW; Kret MR; Lee JT
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery): A Randomized Trial.
    Ott I; Cassese S; Groha P; Steppich B; Voll F; Hadamitzky M; Ibrahim T; Kufner S; Dewitz K; Wittmann T; Kasel AM; Laugwitz KL; Schunkert H; Kastrati A; Fusaro M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28743787
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
    Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
    J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.
    Tomoi Y; Soga Y; Iida O; Fujihara M; Ando K
    J Endovasc Ther; 2017 Oct; 24(5):640-646. PubMed ID: 28675951
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
    Zeller T; Dake MD; Tepe G; Brechtel K; Noory E; Beschorner U; Kultgen PL; Rastan A
    JACC Cardiovasc Interv; 2013 Mar; 6(3):274-81. PubMed ID: 23517839
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Six-Month Results From the Initial Randomized Study of the Ranger Paclitaxel-Coated Balloon in the Femoropopliteal Segment.
    Bausback Y; Willfort-Ehringer A; Sievert H; Geist V; Lichtenberg M; Del Giudice C; Sauguet A; Diaz-Cartelle J; Marx C; Ströbel A; Schult I; Scheinert D;
    J Endovasc Ther; 2017 Aug; 24(4):459-467. PubMed ID: 28558502
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Single-Center Experience of Paclitaxel in the Treatment of Femoropopliteal Disease-No Evidence for an Association With Mortality.
    Linehan V; Doyle M; Barrett B; Gullipalli R
    Vasc Endovascular Surg; 2020 Jul; 54(5):400-405. PubMed ID: 32319355
    [TBL] [Abstract][Full Text] [Related]  

  • 51. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
    Stabile E; Gerardi D; Magliulo F; Zhelev D; Chervenkoff V; Taeymans K; Kotasov D; Goverde P; Giugliano G; Trimarco B; Esposito G
    J Endovasc Ther; 2019 Feb; 26(1):26-30. PubMed ID: 30760132
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Endovascular Management of Femoropopliteal In-Stent Restenosis: A Systematic Review.
    Varela DL; Armstrong EJ
    Cardiovasc Revasc Med; 2019 Oct; 20(10):915-925. PubMed ID: 30447898
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role for DCBs in the treatment of ISR.
    Bague N; Nasr B; Chaillou P; Costargent A; Gouailler-Vulcain F; Goueffic Y
    J Cardiovasc Surg (Torino); 2016 Aug; 57(4):578-85. PubMed ID: 27102629
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study.
    Dake MD; Scheinert D; Tepe G; Tessarek J; Fanelli F; Bosiers M; Ruhlmann C; Kavteladze Z; Lottes AE; Ragheb AO; Zeller T;
    J Endovasc Ther; 2011 Oct; 18(5):613-23. PubMed ID: 21992630
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnosis, classification, and treatment of femoropopliteal artery in-stent restenosis.
    Ho KJ; Owens CD
    J Vasc Surg; 2017 Feb; 65(2):545-557. PubMed ID: 28126181
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety of Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease.
    Ouriel K; Adelman MA; Rosenfield K; Scheinert D; Brodmann M; Peña C; Geraghty P; Lee A; White R; Clair DG
    JACC Cardiovasc Interv; 2019 Dec; 12(24):2515-2524. PubMed ID: 31575518
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Angioscopic Findings on 15-Month Follow-Up for Interwoven Nitinol Stent Invagination in the Femoropopliteal Artery.
    Nakama T; Obunai K; Muraishi M; Kojima S; Watanabe H
    JACC Cardiovasc Interv; 2020 Aug; 13(16):1958-1959. PubMed ID: 32739298
    [No Abstract]   [Full Text] [Related]  

  • 58. Intravascular ultrasound guided directional atherectomy versus directional atherectomy guided by angiography for the treatment of femoropopliteal in-stent restenosis.
    Krishnan P; Tarricone A; K-Raman P; Majeed F; Kapur V; Gujja K; Wiley J; Vasquez M; Lascano RA; Quiles KG; Distin T; Fontenelle R; Atallah-Lajam F; Kini A; Sharma S
    Ther Adv Cardiovasc Dis; 2018 Jan; 12(1):17-22. PubMed ID: 29265002
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Quantitative Angiographic Comparison of Restenotic Tissue Following Placement of Drug-Eluting Stents and Bare Metal Stents in Symptomatic Patients With Femoropopliteal Disease.
    Ansel GM; Jaff MR; Popma JJ; Battisti AJ; Lottes AE; Harnish P; Dake MD
    J Endovasc Ther; 2017 Aug; 24(4):499-503. PubMed ID: 28485182
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Spot stenting versus full coverage stenting after endovascular therapy for femoropopliteal artery lesions.
    Tomoi Y; Soga Y; Takahara M; Fujihara M; Iida O; Kawasaki D; Ando K
    J Vasc Surg; 2019 Oct; 70(4):1166-1176. PubMed ID: 30850285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.